Prognosis of chronic inflammatory demyelinating poly-neuropathy KU Leuven
The invention relates to the use of serum neurofilament light chain (sNfL) as a marker for predicting disease progression or therapy response in a Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patient.